At Tris Pharma, we’re on a mission to uniquely solve some of the most intractable therapeutic challenges in ADHD, pain, addiction and other diseases of the central nervous system Learn MoreBREAKING NEWS Tris Pharma Announces Positive Results from ALLEVIATE-2 Phase 3 Pivotal Trial for Cebranopadol...
The mission of the Women’s Business Council is to make a positive impact at Tris Pharma by strengthening and promoting the personal and professional development of women. We seek to empower, inspire and celebrate women by providing access and opportunities to learn, network and share their expert...
医疗健康 医药服务 所属公司:Tris Pharma 当前融资轮次:种子轮 成立日期:2000-01-01 所属地:美国 简介:Tris Pharma,Inc。专注于制药科学和技术产品的开发。具体而言,我们从事品牌产品和特种通用产品的研究,开发,制造和商业化。基于我们众多的NDA和ANDA以及30多项美国授权专利的丰富且不断增长的产品组合,我们在美国...
Tris Pharma 美国仿制药品研发商 认领企业 委托联系 未融资 运营中 美国 | 查看官网 Tris Pharma是一家美国仿制药品研发商,致力于药物科学和技术产品的开发,拥有DYANAVEL®XR(苯丙胺)、DYANAVEL®XR(苯丙胺)、QuillivantXR®(盐酸哌醋甲酯)等专利药品。
DYANAVEL and LiquiXRare registered trademarks and ONYDA is a trademark of Tris Pharma, Inc. Quillivant XR and QuilliChew ER are registered trademarks of NextWave Pharmaceuticals, Inc. All other trademarks are the property of their respective owners. ...
While Tris Pharma makes reasonable efforts to include accurate, up-to-date information on the site, Tris Pharma makes no warranties or representations as to its accuracy. Tris Pharma assumes no liability for any errors or omissions in the content of the site. ...
DYANAVEL and LiquiXRare registered trademarks and ONYDA is a trademark of Tris Pharma, Inc. Quillivant XR and QuilliChew ER are registered trademarks of NextWave Pharmaceuticals, Inc. All other trademarks are the property of their respective owners. ...
大火医生聊健康超话Tris Pharma公司今日宣布,其在研疗法cebranopadol在关键性3期临床试验ALLEVIATE-1中取得了积极的顶线结果。这一试验评估了cebranopadol治疗腹壁整形手术后中度至重度急性疼痛的疗效。该结果进一步支持了cebranopadol的良好疗效和安全性数据。Cebranopadol是一种潜在“first-in-class”的疼痛治疗药物,作用机制为...
While Tris Pharma makes reasonable efforts to include accurate, up-to-date information on the site, Tris Pharma makes no warranties or representations as to its accuracy. Tris Pharma assumes no liability for any errors or omissions in the content of the site. ...
1/22,Tris Pharma计划在今年提交其实验性疼痛治疗药物cebranopadol的监管申请。该药物在关键性III期ALLEVIATE-1试验中达到了主要终点,在腹壁整形术后患者中与安慰剂相比显著减少了中度至重度急性疼痛,具有统计学意义。 Cebranopadol(也称为TRN-228)是一种同时激动nociceptin/orphanin FQ肽(NOP)受体和µ-阿片肽(MOP)受...